Highlighting Progress in Myeloma Treatment: POLLUX Trial Final Overall Survival Results With Daratumumab-Based Therapy
The updated results of the POLLUX trial, reported in the Journal of Clinical Oncology by Dimopoulos and colleagues and in this issue of The ASCO Post, showed...
Making the Art of Oncology and Cancer Care Central to Her Presidential Term
Lynn M. Schuchter, MD, FASCO, has said that volunteering and working with ASCO over many years has been the highlight of her career. She served on...
Partnering With Patients: The Cornerstone of Cancer Care and Research
The health and well-being of our clinicians, our communities, and our care systems need vigilance now more than ever to ensure we keep pace with the...
KRYSTAL-1 Update: Adagrasib Yields Benefit in Variety of KRAS G12C–Mutated Tumors
In the phase I/II KRYSTAL-1 trial, the KRAS inhibitor adagrasib demonstrated clinical activity in previously treated patients with pancreatic ductal adenocarcinoma...
Immunotherapy/Chemotherapy Combination Prolongs Survival in Advanced Biliary Tract Cancers
The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival...
Anne Chiang and Roy S. Herbst: How Telemedicine Can Transform Clinical Research and Practice
Joyce Kurisko and Coauthors: Cancer Drugs and Price Controls: Is It Time?
Narjust Florez (Duma): My White Coat Doesn’t Fit
S. Monica Soni: The Shades of Gray in Delivery of Goal-Concordant Care
Lee N. Newcomer: EQRx Pricing Strategy
Sponsored Content
Sponsored by Bristol Myers Squibb
First-Line Treatment of PD-L1–Negative Non–Small Cell Lung Cancer
Sponsored by Lilly Medical Affairs
Optimizing Outcomes for Patients With Hormone Receptor–Positive/ HER2-Negative Early Breast Cancer
Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab as First-Line Treatment for Patients With Advanced Esophageal Cancer
The first results from the phase III CheckMate 648 study represent significant progress in the treatment of patients with advanced esophageal squamous cell carcinoma. The trial evaluated first-line treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab in patients with advanced...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Ponatinib/Blinatumomab Demonstrates High Rates of Complete Molecular Response in Philadelphia Chromosome–Positive ALL
The combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). The study—presented by Nicholas J. Short, MD, and colleagues during the 2021 ASCO...
Effect of the COVID-19 Pandemic on Delivery of Oncology Services in India
In a study reported in The Lancet Oncology, Ranganathan et al quantified the enormous impact of the COVID-19 pandemic on delivery of cancer services in India. Study Details The study involved data from 41 cancer centers across the nation. The delivery of oncology services between March 1 and May...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Organizations Issue Statement Encouraging Return to HPV Vaccination
Doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations recently issued a joint statement urging the nation’s health-care systems, physicians, parents, children, and young adults to get human papillomavirus (HPV) vaccination back on ...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
